Anhui Fengyuan Pharmaceutical Co., Ltd.

Sümbol: 000153.SZ

SHZ

8.55

CNY

Turuhind täna

17.7110
P/E suhe
0.1358
PEG suhe
2.84B
MRK Cap
0.01%
DIV tootlus

Anhui Fengyuan Pharmaceutical Co., Ltd. (000153-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 1464.253 M, mis on 0.206 % gowth. Kogu perioodi keskmine brutokasum on 433.999 M, mis on 0.211 %. Keskmine brutokasumi suhtarv on 0.311 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 0.031 %, mis on võrdne 0.332 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Anhui Fengyuan Pharmaceutical Co., Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus -0.017. Käibevara valdkonnas on 000153.SZ aruandlusvaluutas 1902.911. Märkimisväärne osa neist varadest, täpsemalt 319.905, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust -0.094%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 575.808, kui neid on, aruandlusvaluutas. See näitab erinevust 1.596% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 194.964 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on -0.127%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 1889.41 aruandlusvaluutas. Selle aspekti aastane muutus on 0.093%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 984.777, varude hind on 573.58 ja firmaväärtus 7.92, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 285.63. Kontovõlad ja lühiajalised võlad on vastavalt 746.11 ja 492.8. Koguvõlg on 687.76, netovõlg on 367.86. Muud lühiajalised kohustused moodustavad 10.19, mis lisandub kohustuste kogusummale 2472.49. Lõpuks hinnatakse viidatud aktsia 0, kui see on olemas.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998
balance-sheet.row.cash-and-short-term-investments	1104.98	319.9	353.1	251.3	282.3	360.6	311.4	275.9	176.5	164.9	167.9	308.9	65.7	57.4	96.4	107.3	109.7	59.5	81.4	159.9	128.2	59	95	208.1	381.2	4.4	1.7	3.3
balance-sheet.row.short-term-investments	-860.53	-213.4	80.7	-226.9	7	9.9	7.8	13.5	20.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.net-receivables	4181.1	984.8	925.9	839.2	887.9	864.7	811.5	809.5	719	497.4	554.6	423.7	382.8	349.2	318.6	397.5	367.3	392.4	511.3	261.2	259.3	173	129.3	101.3	2.5	2.2	2	2.5
balance-sheet.row.inventory	2298.35	573.6	699.1	569.5	527.2	486.8	461	402.3	274.4	270.2	253.9	212.3	201.6	179.2	153.1	132.7	140.5	111.1	70.3	77.7	45.2	22.1	13.5	30.3	24.8	32.7	20.6	4.6
balance-sheet.row.other-current-assets	155.27	24.7	99.2	34.8	41	27.1	4.3	8.3	10.4	11.7	-28.4	-23.5	-28.7	-23.4	-21.6	-61.9	-55.3	-71.1	-147.1	-32.3	-39.7	-13.9	-13.9	-12.1	55.6	36.1	27.7	15.4
balance-sheet.row.total-current-assets	7739.7	1902.9	2077.4	1694.8	1738.3	1739.2	1588.2	1496	1180.3	944.2	948	921.5	621.5	562.4	546.5	575.6	562.2	491.8	515.9	466.5	393	240.2	223.9	327.6	464.1	75.3	51.9	25.8
balance-sheet.row.property-plant-equipment-net	6019.73	1513.9	1461.7	1223.5	1044.1	877.1	806.6	817.3	856.2	906.4	871.2	719.7	612.1	544.9	536.6	509	484.3	475.6	495.5	462.6	450	447.1	408.5	348.2	169.2	57.8	56.5	25.8
balance-sheet.row.goodwill	31.68	7.9	7.9	7.9	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.5	11.5	7.9	7.9	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	1126.56	285.6	244.9	225.8	208.8	171.3	166.5	136.2	138.5	177.1	174.6	172.1	168.2	165.2	148.1	67.8	69.4	69.4	15.7	19.9	23.1	24.6	27	8.4	0.3	0.2	0	0
balance-sheet.row.goodwill-and-intangible-assets	1158.24	293.5	252.8	233.7	220.3	182.8	178	147.8	150	188.6	186.2	183.7	179.7	176.7	159.6	79.3	77.3	77.3	15.7	19.9	23.1	24.6	27	8.4	0.3	0.2	0	0
balance-sheet.row.long-term-investments	2388.93	575.8	566.8	556.4	312.7	423.1	212.5	117.8	109.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.tax-assets	213.4	60.2	40	37.5	21	21.6	18	13.8	10.4	6.3	5.6	6.3	7.1	5.8	5.8	5.7	6.1	8.4	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-non-current-assets	162.13	45	70.6	70.4	299.9	315.8	204.8	175	183.9	259.8	226.6	149.9	30.1	28.4	27.3	35.9	35.7	35.5	38.5	143.7	29.9	25	25	25.3	1.1	1.3	1.9	7.3
balance-sheet.row.total-non-current-assets	9942.45	2488.4	2391.8	2121.6	1897.9	1820.4	1419.8	1271.8	1310.1	1361.1	1289.6	1059.6	829	755.8	729.3	629.9	603.3	596.8	549.7	626.2	502.9	496.7	460.5	381.9	170.7	59.3	58.4	33.1
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	17682.15	4391.3	4469.2	3816.3	3636.2	3559.6	3008	2767.7	2490.4	2305.3	2237.5	1981	1450.5	1318.2	1275.8	1205.5	1165.6	1088.6	1065.6	1092.7	895.9	736.9	684.4	709.5	634.8	134.6	110.3	58.9
balance-sheet.row.account-payables	2940.77	746.1	722.7	612.9	712.3	962.3	781.5	557.4	439.4	282.7	280.3	203.9	176.6	163.6	148.2	149.4	221.2	145.4	100.5	97.2	64.1	32.3	27.6	26.4	16.9	14.8	15.3	9
balance-sheet.row.short-term-debt	2171.78	492.8	598.4	501.1	582.6	492.8	367.2	509.8	530	493	463.2	275.5	279.5	258.2	231.4	211.4	218.5	174.8	253.7	308	171.5	75	40	70	44	29.6	17.4	10.5
balance-sheet.row.tax-payables	201.48	49.9	68.1	43.5	45.4	40.5	36.5	44.4	38.8	13.3	4.9	7.2	-3.4	-1.5	8.3	9.1	5.3	12.2	8.9	-5.3	-2.4	-1.9	-0.5	5.3	10.2	3.1	2.7	2
balance-sheet.row.long-term-debt-total	944.12	195	189.6	114	27	105.1	0	0	43	59.4	67.8	197	60	0	40	70	0.9	0.9	0	0	0	0	3.5	0	5	8	13	10.1
Deferred Revenue Non Current	795.47	238	151.9	150.9	77.3	78.9	59	38.7	25.6	17.2	18.6	52.1	0	0	0	-70	0	0	0	0	0	0	0	0	-5	0	0	0
balance-sheet.row.deferred-tax-liabilities-non-current	104.89	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	37.21	10.2	766.3	15.9	13.6	64.7	454.7	48.8	47.5	23.8	35.8	28	26.3	26.5	17	25.4	16.8	8.4	13.8	9	10.1	13.3	8.1	15.3	0.6	5.6	1.2	5.3
balance-sheet.row.total-non-current-liabilities	1844.48	458.9	369.8	338.2	123.1	197.8	76.2	57.6	86.5	143.2	152	271.7	63.8	3.3	43	72.5	3.4	3.4	0.9	0.9	0.9	0.9	3.5	0	11.2	8	13	10.1
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	74.55	20.2	20.7	28	38.3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	10056.97	2472.5	2714.5	2258.6	2188.2	2232.5	1716.2	1547.3	1337.6	1121	1090.6	926.7	675.5	553	522	526.8	511.5	449.7	445.1	493.1	304.9	160.9	123.5	173.3	102.3	81.6	66	34.9
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	1328.27	332	332.1	312.1	312.1	312.1	317.1	317.1	312.1	312.1	312.1	312.1	260	260	260	260	260	260	260	260	130	130	65	65	65	40	40	20.6
balance-sheet.row.retained-earnings	3532.26	888.7	764.4	629.3	518.9	417.2	370.2	312	246.7	250	217.6	176.6	180.5	188.6	179.5	140.7	118.6	104.9	88.6	68.8	61.1	53	53.8	33.1	29.8	7.5	0.1	2.4
balance-sheet.row.accumulated-other-comprehensive-income-loss	919.43	53.1	595.2	112.2	107.9	120.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	1733.96	615.5	36.8	474.6	474.6	474.6	601.4	591.3	593.9	588.6	582.7	524.9	293.7	274.9	274.1	270.8	269	268.5	266.8	265.8	394.5	393	442.1	437	436.6	4.4	3.2	1
balance-sheet.row.total-stockholders-equity	7513.92	1889.4	1728.5	1528.2	1413.5	1324.3	1288.7	1220.5	1152.8	1150.7	1112.4	1013.6	734.2	723.5	713.5	671.5	647.6	633.4	615.4	594.6	585.6	576	560.9	535.1	531.4	51.9	43.3	24
balance-sheet.row.total-liabilities-and-stockholders-equity	17682.15	4391.3	4469.2	3816.3	3636.2	3559.6	3008	2767.7	2490.4	2305.3	2237.5	1981	1450.5	1318.2	1275.8	1205.5	1165.6	1088.6	1065.6	1092.7	895.9	736.9	684.4	709.5	634.8	134.6	110.3	58.9
balance-sheet.row.minority-interest	111.26	29.4	26.3	29.5	34.5	2.8	3.1	0	0	33.6	34.5	40.7	40.9	41.8	40.3	7.2	6.5	5.5	5.1	5	5.5	0	0	1.1	1.1	1.1	1.1	1.1
balance-sheet.row.total-equity	7625.18	1918.8	1754.8	1557.7	1448	1327.1	1291.8	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	17682.15	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	1528.4	362.4	371.5	329.5	319.7	433	220.3	131.3	129.7	107.9	101	25	25	25	25	34.2	34.2	34.2	36.9	141.7	28.6	25	25	25.3	0.8	1.3	1.9	7.3
balance-sheet.row.total-debt	3115.9	687.8	788	615.1	609.6	597.9	367.2	509.8	573	552.4	531	472.5	339.5	258.2	271.4	281.4	218.5	174.8	253.7	308	171.5	75	43.5	70	49	37.6	30.4	20.6
balance-sheet.row.net-debt	2010.92	367.9	434.8	363.8	334.3	247.2	63.6	247.4	416.5	387.5	363.1	163.6	273.8	200.8	175	174.1	108.8	115.3	172.3	148.1	43.3	16	-51.5	-138.2	-332.2	33.2	28.7	17.3

Rahavoogude aruanne

Anhui Fengyuan Pharmaceutical Co., Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.713 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab -0.026 erinevust võrreldes eelmise aastaga. Huvitav on see, et osa ettevõtte aktsiatest, täpsemalt 0, ostis ettevõte ise tagasi. Selle tegevuse tulemusena muutus 0.000 võrreldes eelmise aastaga. Vahepeal on ettevõtte võlgnevused praegu 261.41 aruandlusvaluutas. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli -99392650.670. See on -0.336 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 121.7, 308.31, -804.3, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -57.48 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 599.51, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2021	2019	2017	2015	2013	2011	2009	2007	2005	2003	2001	1999
cash-flows.row.net-income	160.27	150.9	109.5	102.1	80.6	60.7	65.3	45.7	31.5	41.1	27.2	18.1	9.9	40.5	23.7	15.2	5.9	22.1	9.3	10	18.1	25.8	24.8	26.3	8.6
cash-flows.row.depreciation-and-amortization	98.78	121.7	76.8	70.9	70.6	74.8	74.8	68.8	63.2	68.8	58.8	52.4	50.2	49.6	44.8	41.2	39.3	30.1	32.1	27.8	23.4	15.2	9.4	5.5	3.7
cash-flows.row.deferred-income-tax	-11.32	-5.7	-10.3	5.6	-7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	18.88	5.7	10.3	-5.6	7.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	-112.36	121.5	-4.6	73.8	-127.9	44.2	-142.3	-71	-83.7	-124.7	-61.4	-51.6	-19.3	-38	-46.2	-25.3	-21	-6.7	-21.6	-56.4	-50.5	-38.7	-19.8	-6.6	-14.3
cash-flows.row.account-receivables	-238.77	-89.3	-114.1	44.8	-7.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	126.41	-44.9	-42.3	-40.7	-23.3	-58.5	-129.4	-5.5	-16.3	-41.6	-12.1	-19.8	-26.4	-20.2	8.7	-28.8	-41.3	7.1	-32.2	-4.5	-9	-0.2	-6.4	7.9	-12.1
cash-flows.row.account-payables	0	261.4	138.8	-44.8	7.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	0	-5.7	12.9	114.5	-104.6	102.7	-12.9	-65.4	-67.4	-83.1	-49.3	-31.7	7	-17.8	-54.9	3.5	20.3	-13.8	10.6	-51.9	-41.5	-38.5	-13.4	-14.5	-2.2
cash-flows.row.other-non-cash-items	115.12	45.8	56.2	46	43	53.9	54.5	34.7	34.5	25.3	-95	26.7	14.2	3	10.1	18.7	31.1	-9.2	15.1	6.9	-2.5	8.2	9.1	0.7	3
cash-flows.row.net-cash-provided-by-operating-activities	250.48	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-153.03	-81.8	-157.4	-190.7	-145.6	-84.6	-48	-22.2	-50.3	-175.9	-113.9	-95.1	-69.9	-89.7	-74.4	-31.6	-35.2	-136.7	-35.7	-47	-56.6	-91.4	-190.2	-117.8	-4.6
cash-flows.row.acquisitions-net	7.94	-302.7	1	4.3	145.6	1.8	1	-34.7	0	0	0	95.1	0	100.5	-12.5	0	1.7	-1.7	22	0	0	0	0	0	0
cash-flows.row.purchases-of-investments	-85	-29	-1	-31.9	-221.8	-104.8	-27.7	-49.2	0	0	0	-7.2	0	-0.2	74.6	0	-2.6	-0.2	-166.6	-16.6	0	0	-25	0	0
cash-flows.row.sales-maturities-of-investments	0.15	5.7	7.2	133.1	4.4	5.7	39.9	35.1	6.9	11	3.7	3.7	3.7	36.7	6.7	5.7	41	70	54.1	0	0	0	0	0	0
cash-flows.row.other-investing-activites	-76.6	308.3	0.4	0.4	-145.6	20	0	13.2	0	0	60.2	-95.1	0	-89.7	-74.4	1	25.5	25.2	1.7	52.1	2.2	-1.8	0	0	0
cash-flows.row.net-cash-used-for-investing-activites	-229.62	-99.4	-149.7	-84.9	-363	-162	-34.7	-57.8	-43.4	-164.9	-50.1	-98.5	-66.2	-42.5	-80	-24.8	30.5	-43.4	-124.5	-11.5	-54.5	-93.2	-215.2	-117.8	-4.6
cash-flows.row.debt-repayment	-588.23	-804.3	-942.9	-1157.2	-845	-780.7	-685	-695.4	-588.6	-329	-297.9	-278.2	-231.4	-231.4	-238.2	-174.8	-266.1	-389.1	-171.5	-75	-83.5	-57	-97	-28.5	-11.4
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	-0.35	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-62.48	-57.5	-25.6	-38.4	-51.7	-31.7	-34.4	-60.4	-30.8	-32	-50.8	-20.9	-16.2	-14.9	-17.7	-18.4	-16.2	-17.1	-15.2	-6.5	-4.7	-16.9	-7.4	-2.6	-2.9
cash-flows.row.other-financing-activites	358.44	599.5	862.5	985.8	1183.8	800.5	767.4	708	610	374.4	712.1	359.5	219.7	222.9	301.1	218.5	174.8	334.8	308	173.9	118.2	43.5	123	499.9	20.6
cash-flows.row.net-cash-used-provided-by-financing-activities	55.59	-262.3	-106	-209.8	287.1	-11.9	48	-47.8	-9.5	13.4	363.4	60.4	-27.9	-23.4	45.2	25.3	-107.5	-71.4	121.3	92.4	30	-30.4	18.6	468.8	6.3
cash-flows.row.effect-of-forex-changes-on-cash	0.21	0.1	-0.3	-0.6	0	0.3	-0.2	0.1	0.1	0	0.2	0	0	0	0	-0.1	-0.1	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	76.66	78.4	-18.2	-2.5	-9.7	60	65.5	-27.3	-7.3	-141	243.2	7.6	-39	-10.8	-2.4	50.2	-21.9	-78.5	31.7	69.2	-36	-113.1	-173.1	376.8	2.7
cash-flows.row.cash-at-end-of-period	1001.66	344.7	234.6	252.8	255.3	265	205	139.5	160.6	167.9	308.9	65.7	57.4	96.4	107.3	109.7	59.5	81.4	159.9	128.2	59	95	208.1	381.2	4.4
cash-flows.row.cash-at-beginning-of-period	925	266.3	252.8	255.3	265	205	139.5	166.8	167.9	308.9	65.7	58.1	96.4	107.3	109.7	59.5	81.4	159.9	128.2	59	95	208.1	381.2	4.4	1.7
cash-flows.row.operating-cash-flow	250.48	440	237.9	292.8	66.2	233.6	52.4	78.2	45.5	10.5	-70.3	45.7	55.1	55	32.4	49.8	55.3	36.3	34.9	-11.7	-11.5	10.5	23.6	25.9	1
cash-flows.row.capital-expenditure	-153.03	-81.8	-157.4	-190.7	-145.6	-84.6	-48	-22.2	-50.3	-175.9	-113.9	-95.1	-69.9	-89.7	-74.4	-31.6	-35.2	-136.7	-35.7	-47	-56.6	-91.4	-190.2	-117.8	-4.6
cash-flows.row.free-cash-flow	97.45	358.2	80.5	102	-79.4	149	4.4	56	-4.8	-165.3	-184.2	-49.4	-14.8	-34.7	-42	18.2	20.1	-100.4	-0.8	-58.7	-68.1	-80.9	-166.7	-91.9	-3.6

Kasumiaruande rida

Anhui Fengyuan Pharmaceutical Co., Ltd. tulud muutusid võrreldes eelmise perioodiga 0.068%. 000153.SZ brutokasum on teatatud 1099.15. Ettevõtte tegevuskulud on 857.07, mille muutus võrreldes eelmise aastaga on -4.546%. Kulud amortisatsioonikulud on 121.7, mis on -0.205% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 857.07, mis näitab -4.546% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab 0.055% kasvu võrreldes eelmise aastaga. Tegevustulu on 213.25, mis näitab 0.055% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 0.031%. Eelmise aasta puhaskasum oli 159.29.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006	2004	2002	2000	1998
income-statement-row.row.total-revenue	4189.99	4275.4	4004	3501.7	3321.2	3238.1	3013.4	2578.1	2033.7	1554.3	1698.9	1529.9	1657.8	1516.5	1074.2	955.7	873.8	703.8	521.3	441.2	280.5	179.1	157.9	159.2	114.1	57.2	49.6	44.1
income-statement-row.row.cost-of-revenue	3142.57	3176.3	2873.7	2447.4	2170	2002.6	1839.7	1789.2	1492.5	1136.7	1248.7	1131.3	1276.8	1213.2	788.8	693.5	640.3	527.9	392.3	328.8	205.7	110.2	86	80.7	69.5	35.6	31.5	28.2
income-statement-row.row.gross-profit	1047.42	1099.1	1130.3	1054.3	1151.2	1235.5	1173.7	788.9	541.2	417.6	450.2	398.6	380.9	303.3	285.3	262.2	233.6	175.9	129	112.4	74.9	68.9	72	78.5	44.7	21.6	18.1	15.9
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	64.97	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	34.67	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	543.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	1.43	1.6	117.7	103.7	99	96.3	0.5	0.5	76	11.9	10.5	12.8	12.2	6.3	13.7	5.3	0.7	0.8	27	2.7	0.3	1.4	2	1.1	1.3	0.2	0	0
income-statement-row.row.operating-expenses	793.23	857.1	897.9	863.7	990.3	1078.2	1034.8	655.7	449.2	357.2	384.4	347.3	343.7	283.2	242.6	228.5	196.8	132	108.4	91.4	55.5	45.9	37.5	48.8	13.7	10.2	8.1	8
income-statement-row.row.cost-and-expenses	3935.8	4033.4	3771.6	3311.1	3160.3	3080.8	2874.5	2445	1941.7	1493.9	1633.2	1478.6	1620.6	1496.4	1031.4	922	837.1	659.9	500.6	420.2	261.2	156.1	123.5	129.4	83.2	45.8	39.6	36.2
income-statement-row.row.interest-income	10.21	8.7	5.4	3.1	3.7	3.9	4.1	2.5	2.2	2.1	2.9	3	0.6	0.5	0.9	3.5	1.3	1.6	3.9	1.9	3.2	4.4	3	5.1	1.8	0	0	0
income-statement-row.row.interest-expense	31.84	33.9	32.9	38.6	39.5	37.1	31	32.4	28.5	31.9	32.1	22.1	20.6	16.3	14.5	17.7	18.4	16.2	19.6	14.6	6.5	3.3	2.2	3.7	2.5	2.1	1.8	2.2
income-statement-row.row.selling-and-marketing-expenses	543.4	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	1.43	1.6	0.2	3.7	-47.8	-4.2	-45.8	-36.5	-25.4	-18.3	-9.4	-10.2	-11.9	-6.3	9.8	-1.6	-16.2	-28.1	15.6	-11.1	-4.4	3.6	-0.8	1.9	-0.1	-2.6	-2.3	-2.4
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	1.43	1.6	117.7	103.7	99	96.3	0.5	0.5	76	11.9	10.5	12.8	12.2	6.3	13.7	5.3	0.7	0.8	27	2.7	0.3	1.4	2	1.1	1.3	0.2	0	0
income-statement-row.row.total-operating-expenses	1.43	1.6	0.2	3.7	-47.8	-4.2	-45.8	-36.5	-25.4	-18.3	-9.4	-10.2	-11.9	-6.3	9.8	-1.6	-16.2	-28.1	15.6	-11.1	-4.4	3.6	-0.8	1.9	-0.1	-2.6	-2.3	-2.4
income-statement-row.row.interest-expense	31.84	33.9	32.9	38.6	39.5	37.1	31	32.4	28.5	31.9	32.1	22.1	20.6	16.3	14.5	17.7	18.4	16.2	19.6	14.6	6.5	3.3	2.2	3.7	2.5	2.1	1.8	2.2
income-statement-row.row.depreciation-and-amortization	53.36	126.3	158.9	125.4	70.9	108.5	74.8	74.8	68.8	63.2	68.8	58.8	52.4	50.2	49.6	44.8	41.2	39.3	30.1	32.1	27.8	23.4	15.2	9.4	5.5	3.7	2.3	2.4
income-statement-row.row.ebitda-caps	267.41	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	214.06	213.3	202.1	146	185.9	124.1	92.5	96.1	62.9	30.2	45.9	28.5	14.6	7.9	39.6	26.9	19.9	15	12.4	11.2	16.5	24.1	31.7	30.6	29.5	8.6	7.8	5.5
income-statement-row.row.income-before-tax	215.48	214.9	202.3	149.7	138.1	119.9	93.1	96.7	66.6	42.1	56.4	41.1	25.3	13.8	52.6	32.1	20.6	15.8	37.8	11.9	15.8	26.6	33.7	31.7	30.9	8.8	7.8	5.5
income-statement-row.row.income-tax-expense	57.47	57.6	51.4	40.3	36	39.3	32.4	31.3	20.8	10.6	15.3	14	7.2	3.9	12.1	8.4	5.4	9.9	15.7	2.6	5.8	8.5	7.9	6.9	4.6	0.1	0.1	1
income-statement-row.row.net-income	160.27	159.3	154.4	123	103.7	80.9	60.9	65.3	45.8	32.4	41	27.3	19	9.9	41.6	23	14.2	5.6	22	9	9.6	18.1	25.8	24.8	26.3	8.6	7.7	4.5